He is currently chairman of the Singapore Hepatology Conference and Science of HBV cure conference and was the Chairman of the Asia Pacific Association for Study of the Liver (APASL) Liver Week 2013 Congress. He was appointed in 2014 to the governing council of the International Association for Study of Liver (IASL). He was previously the chairman of the Evidence Based Medicine Subcommittee at National University Hospital, and chairman of the Asia Pacific Evidence Based Medicine Workshop. He has research interests in clinical trials of new treatments for chronic hepatitis B and C (where he has been principal investigator in many clinical trials). He has a particular interest in translational research in viral hepatitis, involving molecular biology and immunology of hepatitis, and runs an active laboratory investigating the impact on viral evolution in hepatitis B and HBV lifecycle events. In addition he has a diversity of clinical research interests ranging from cost-effective analysis to health related quality of life analysis and treatment outcomes. Professor Lim has over 207 peer review publications and has been awarded over $32 million in grant funding for his research, including an award of a $25 million National Translational Clinical Research (TCR) grant in 2015 to investigate eradication of HBV, which has been renewed in 2020. He also holds a Senior Clinician Scientist Award Grant to study B cell Immunology of HBV.